Market Place
Sourcing Support
Tectonic Presents Positive TX45 Phase 1a Results at AHA 2024
11 Nov 2024 //
GLOBENEWSWIRE
Tectonic Announces Q3 2024 Financial Results & Business Highlights
07 Nov 2024 //
GLOBENEWSWIRE
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
22 Oct 2024 //
GLOBENEWSWIRE
Tectonic Therapeutic Announces Phase 1a Results For TX45
19 Sep 2024 //
GLOBENEWSWIRE
Tectonic Therapeutic to Participate in September Investor Conferences
20 Aug 2024 //
GLOBENEWSWIRE
Tectonic Therapeutic Announces Q2 2024 Financial Results And Business Highlights
14 Aug 2024 //
GLOBENEWSWIRE
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
30 Jul 2024 //
GLOBENEWSWIRE
Tectonic Closes AVROBIO Merger And Raises $130.7M In Concurrent Placement
20 Jun 2024 //
BUSINESSWIRE
Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
03 Jun 2024 //
BUSINESSWIRE
Tectonic initiates Phase 1B for TX45 in Group 2 PH with HFpEF
26 Mar 2024 //
BUSINESSWIRE
Tectonic Therapeutic Announces Participation at Investor Conferences in March
27 Feb 2024 //
BUSINESSWIRE
Tectonic Announces Start of First Clinical Program for GPCR-Targeted Biologic
28 Nov 2023 //
BUSINESSWIRE
Tectonic Therapeutic Strengthens Leadership Team
19 Jul 2022 //
BUSINESSWIRE
Tectonic snags Regeneron`s Dupixent program leader as CMO
22 Jul 2021 //
FIERCEBIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.